Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.
Cell Stem Cell. 2020 Oct 1;27(4):523-531. doi: 10.1016/j.stem.2020.09.014.
Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable diseases and injuries. Both ESCs and iPSCs are already being used in clinical trials. However, we continue to encounter practical issues that limit their use, including their inherent properties of tumorigenicity, immunogenicity, and heterogeneity. Here, I review two decades of research aimed at overcoming these three difficulties.
人类多能干细胞，如胚胎干细胞（ESCs）和诱导多能干细胞（iPSCs），为对抗难治性疾病和损伤的细胞疗法提供了前所未有的机会。ESCs 和 iPSCs 已经在临床试验中得到应用。然而，我们仍然遇到了限制它们使用的实际问题，包括它们固有的致瘤性、免疫原性和异质性。在这里，我回顾了过去 20 年旨在克服这三个困难的研究。
